Long-term response of immune thrombocytopenia to extracorporeal immunoadsorption

The Lancet ◽  
1991 ◽  
Vol 337 (8749) ◽  
pp. 1106 ◽  
Author(s):  
J.P. Balint ◽  
H.W. Snyder ◽  
S.K. Cochran ◽  
F.R. Jones
2013 ◽  
Vol 48 (4) ◽  
pp. 297 ◽  
Author(s):  
Laura Scaramucci ◽  
Marco Giovannini ◽  
Andrea Tendas ◽  
Pasquale Niscola ◽  
Paolo de Fabritiis

2017 ◽  
Vol 98 (4) ◽  
pp. 371-377 ◽  
Author(s):  
Miriam Marangon ◽  
Nicola Vianelli ◽  
Francesca Palandri ◽  
Maria Gabriella Mazzucconi ◽  
Cristina Santoro ◽  
...  

2016 ◽  
Vol 135 (3) ◽  
pp. 162-171 ◽  
Author(s):  
Young Hoon Park ◽  
Hyeon Gyu Yi ◽  
Chul Soo Kim ◽  
Junshik Hong ◽  
Jinny Park ◽  
...  

Background: Because many physicians seem reluctant to recommend splenectomy for elderly patients with immune thrombocytopenia (ITP), we investigated the safety and efficacy of splenectomy and the predictive factors for response in these patients. Methods: 184 patients with primary ITP were retrospectively analyzed based on age at splenectomy: an elderly group (≥60 years, n = 52) and a younger group (<60 years, n = 132). Results: There was no difference in the response rate of elderly versus younger patients (80.7 vs. 80.3%, p = 0.466). Relapse (45.2 vs. 22.6%, p = 0.006), complications, and median postoperative stay (9.5 vs. 7 days, p = 0.019) were significantly higher in the elderly group. The 5-year relapse-free survival of responders was 51.8% in the elderly group and 76.3% in the younger group (p = 0.002). Response to any treatment before splenectomy (HR 2.9, 95% CI: 1.24-6.80, p = 0.014) and platelet count on postoperative day 14 ≥200 × 109/l (HR 31.43, 95% CI: 4.15-238.28, p = 0.001) were independent factors for a favorable response. Conclusions: Age ≥60 years did not influence the response to splenectomy but was associated with increased relapse and postoperative complications. Splenectomy could provide a durable long-term response for elderly ITP patients.


2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Germame Ajebo ◽  
Paul Dainer ◽  
Jeremy Pantin ◽  
Nathan Ryan ◽  
Charles Bruker

Author(s):  
Giuseppe Lassandro ◽  
Valentina Palladino ◽  
Giovanni Carlo Del Vecchioa ◽  
Viviana Valeria Palmieri ◽  
Paola Carmela Corallo ◽  
...  

Background and Objective: Immune thrombocytopenia (ITP) is a common bleeding disorder in childhood. The management of ITP in children is controversial, requiring personalized assessment of patients and therapeutic choices. Thrombopoietin receptor agonists (TPO-RAs), eltrombopag and romiplostim, have been shown to be safety and effective for the treatment of pediatric ITP. The aim of our research is defining the role of thrombopoietin receptor agonists in the management of pediatric ITP. Method: This review focuses on the use of TPO-RAs in pediatric ITP, in randomized trials and in clinical routine, highlighting their key role in management of the disease. Results: Eltrombopag and romiplostim appear effective treatment options for children with ITP. Several clinical studies have assessed that the use of TPO-RAs increases platelet count, decreases bleeding symptoms and improves health-related quality of life. Moreover, TPO-RAs are well tolerated with minor side effects. Conclusion: Although TPO-RAs long term efficacy and safety still require further investigations, their use is gradually expanding in clinical practice of children with ITP.


2021 ◽  
pp. 1-19
Author(s):  
Vojtech Kouba ◽  
Juan Camilo Gerlein ◽  
Andrea Benakova ◽  
Marco Antonio Lopez Marin ◽  
Eva Rysava ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document